CoChat
Sign Up
Cited by 1,020Prostate Cancer Diagnosis and TreatmentCancer survivorship and careProstate Cancer Treatment and Research

The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.

Quality-of-Life Outcomes in Men Treated for Localized Prostate Cancer

Litwin, Mark S., Hays, Ron D., Fink, Arlene, Ganz, Patricia A., Leake, Barbara, Leach, Gary E., Brook, Robert H.·1995·JAMA
DOI 10.1001/jama.1995.03520260051032
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To assess health-related quality of life (HRQOL) in men treated for clinically localized prostate cancer. DESIGN: A cross-sectional analysis of HRQOL after treatment with radical prostatectomy, pelvic irradiation, or observation alone for clinically localized prostatic adenocarcinoma, and in age-matched comparison patients. SETTING: A large managed care population in California. SUBJECTS: A total of 528 men, including 214 treated for clinically localized prostate cancer (41 with evidence of metastatic disease were excluded from this analysis) and 273 age-matched, ZIP code-matched comparison patients without prostate cancer. Cancer patients were analyzed in three treatment groups: radical prostatectomy (n = 98), primary pelvic irradiation (n = 56), and observation alone (n = 60). MAIN OUTCOME MEASURES: General HRQOL was measured with the RAND 36-Item Health Survey 1.0. Cancer-specific HRQOL was measured with the CAncer Rehabilitation Evaluation System-Short Form and the Functional Assessment of Cancer Therapy-General form. Disease-targeted quality of life was measured with a new instrument assessing function and bother in three organ systems: sexual, urinary, and bowel. RESULTS: No differences among treatment groups were seen in comparisons of general HRQOL: Significant differences among treatment groups were seen in both function and bother in the prostate-targeted measures of sexual, urinary, and bowel domains. When cancer patients were compared with men of similar age without prostate cancer, differences were seen in the sexual, urinary, and bowel function and bother but not in general HRQOL measures. Although cancer-free men were found not to have full potency or continence, prostate cancer patients treated with surgery or radiation reported significantly worse sexual, urinary, and bowel function than men without cancer. Men who had undergone nerve-sparing prostatectomy did not differ from those who had undergone standard prostatectomy, but the power to detect a difference was low. CONCLUSIONS: Although no differences were seen in general HRQOL, three disease-targeted domains were found to differ significantly among the treatment groups and comparison patients. Even after controlling for the sexual and urinary dysfunction experienced by older men without cancer, those receiving therapeutic interventions for their prostate cancer were found to have poorer disease-targeted HRQOL: We conclude that in addition to general HRQOL, disease-targeted measures must be used to assess outcomes of care in men treated for localized prostate cancer.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.1995.03520260051032

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

Sorted by citations

Items 201–300 of 1,000

Related

See all

Metadata

Authors
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H.
Affiliations
University of California, Los Angeles (US)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
1995-01-11
Volume
273
Issue
2
Pages
129
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.1995.03520260051032
OpenAlex
W1978663841
Cited by
1,020
References
41
Citations by year
2025: 3 · 2024: 4 · 2023: 6 · 2022: 5 · 2021: 11 · 2020: 13 · 2019: 14 · 2018: 12 · 2017: 18 · 2016: 18 · 2015: 24 · 2014: 20 · 2013: 40 · 2012: 38
FWCI
50.62
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
localized prostate cancer, health-related quality of life, radical prostatectomy, pelvic radiotherapy, active surveillance, sexual dysfunction, urinary dysfunction, bowel dysfunction, nerve-sparing radical prostatectomy, cancer-specific quality of life, RAND-36, FACT-G
MeSH terms
Adenocarcinoma, Aged, Analysis of Variance, Cross-Sectional Studies, Humans, Intestines, Male, Prostatectomy, Prostatic Neoplasms, Quality of Life, Radiotherapy, Sexual Behavior, Urinary Tract, Matched-Pair Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review